Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
William G. Wierda(The University of Texas MD Anderson Cancer Center), Mary A. Dwyer(National Comprehensive Cancer Network), Jeremy S. Abramson(Massachusetts General Hospital), Tanya Siddiqi(City Of Hope National Medical Center), Brian T. Hill(Cleveland Clinic), Claudio A. Mosse(Breast Cancer Research Foundation), Sameer A. Parikh(Mayo Clinic), Randall S. Davis(University of Colorado Cancer Center), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Madhav Seshadri(University of California, San Francisco), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Larry D. Cripe(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Jennifer R. Brown(Dana-Farber Cancer Institute), Deborah M. Stephens(University of North Carolina at Chapel Hill), Thomas J. Kipps(University of California San Diego), Danielle M. Brander(Duke University), Matthew J Cortese(Roswell Park Comprehensive Cancer Center), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Farrukh T. Awan(The University of Texas Southwestern Medical Center), Meghan C. Thompson(Memorial Sloan Kettering Cancer Center), Paul Kaesberg(UC Davis Comprehensive Cancer Center), Brad S. Kahl(UW Health University Hospital), Herbert Eradat(University of Colorado Cancer Center), Sameh Gaballa(Johns Hopkins Hospital), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), Stephen J. Schuster(Hospital of the University of Pennsylvania), Bita Fakhri(University of California, San Francisco), Hema Sundar(National Comprehensive Cancer Network), Muhammad Saad Hamid(Piedmont Cancer Institute), Andrew Schorr(Patient Advocate Foundation), Riccardo Valdez(University of Michigan), Greg Bociek(Susan Thompson Buffett Foundation), Manali Kamdar(University of Colorado Cancer Center), S Bilgrami(Yale Cancer Center), Shazia Nakhoda(Fox Chase Cancer Center)
Cited by 83
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k